Sotera Health Company account plan
Global health safeguarding expertise
At a glance
Sotera Health provides sterilization, Co-60 supply and lab testing to healthcare makers; FY2025 revenue was $1,163.6 million across 62 facilities.
Sotera Health (Nasdaq: SHC, Broadview Heights, Ohio) provides end-to-end sterilization, lab testing and advisory services for the healthcare industry, helping make medical, pharmaceutical and food products safe. Its customers in over 50 countries included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies in 2025. FY2025 net revenues were $1,163.6 million (+5.7%), net income $77.9 million and Adjusted EBITDA $593.8 million. It runs 62 facilities with over 3,000 employees, and its former private equity sponsors sold their last shares in May 2026.
Business units
Sterigenics
about 65% of FY2025 revenue ($755.8 million)Outsourced terminal sterilization with gamma, EO, E-beam and now X-Ray across 48 facilities in 13 countries, for more than 2,000 customers in medical devices, pharma and food. FY2025 revenue grew 8.3% at a 54.6% segment margin, and Q3 2026 revenue rose 8.5% to $209.3 million. Led by Mike Rutz.
Nordion
about 16% of FY2025 revenue ($187.6 million)The leading global supplier of Co-60 for sterilization and cancer treatment, and a builder of gamma irradiation systems, sourcing Co-60 from 13 reactors under multi-year contracts. FY2025 margin was 57.3%; Q3 2026 revenue fell 12.4% to $55.0 million on harvest timing while margin rose to 61.3%.
Nelson Labs
about 19% of FY2025 revenue ($220.2 million)Microbiological and analytical chemistry testing with over 900 tests, plus expert advisory services, for about 3,000 medical device and pharma customers. FY2025 revenue fell 3.9% on lower advisory work; Q3 2026 revenue rose 8.8% to $60.6 million. Riaz Bandali now leads it.
Strategic priorities
- Accelerating growth through One Sotera
- CEO Alton Shader's goal is to accelerate growth by selling the full offering across units; about 70% of Sterigenics and Nelson Labs revenue comes from shared customers.
- Sterilization capacity expansion
- The North Carolina X-ray facility started revenue in Q3 2026, and a second greenfield project is due around end of 2027 or early 2028; U.S. EO capacity, especially large chambers, is tight.
- Securing Co-60 supply
- Nordion develops new Co-60 sources with Westinghouse, where PSEG is to be the first U.S. utility producing Co-60, and at the Darlington reactors in Ontario.
- Free cash flow and deleveraging
- Net leverage reached 2.9x against a 2-3x target after a Moody's upgrade; capex should step down meaningfully in 2027, toward the Investor Day free cash flow objective of $500 to $600 million.
- Disciplined M&A
- Management names strategic M&A focused on sterilization services, with share repurchase and debt paydown also evaluated with the board.
Latest results
In Q3 2026 (quarter ended September 30, 2026), net revenues were $324.9 million (+4.4%), net income $58.4 million and Adjusted EBITDA $170.7 million (+3.9%), with the adjusted EBITDA margin up nearly 100 basis points sequentially to 52.5%. Sterigenics grew 8.5% and Nelson Labs 8.8%, while Nordion fell 12.4% on Co-60 harvest timing. For the nine months, revenues were $926.3 million (+7.7%) and Adjusted EBITDA $471.1 million (+7.9%). The 2026 outlook was reaffirmed at revenue of $1.233-1.250 billion and adjusted EBITDA of $632-641 million, with Sterigenics Q4 revenue expected flat sequentially because of softer European med device demand.
Investments and deals
- Capex program
- Capex was $145.5 million in the first nine months of 2026 (vs $87.3 million), with full-year 2026 capex guided at $200-225 million.
- EO facility environmental enhancements
- $24.4 million of 2025 capex and about $51 million expected in 2026 to meet U.S. EPA NESHAP and other rules; the work finishes in Q1 2027.
- X-ray and greenfield sites
- A new X-ray facility in North Carolina began revenue in Q3 2026, and a second greenfield project is back on, due towards the end of 2027 or early 2028.
- Nelson Labs pharma testing expansion
- Lab expansion for pharma testing, with new commercial leadership put in place to drive core lab growth.
- Debt refinancing
- The term loan was repriced in May 2026 to SOFR + 2.25% on $1,415.9 million, maturing May 2031; the weighted average rate fell to 6.44% in Q3 2026.
Challenges and risks
- Ethylene oxide litigation
- About 450 personal injury claims are pending in Georgia and about 120 claims in California, with first trials in January and April 2027; EO litigation and professional fees were $46.2 million in 2025.
- Co-60 supply concentration
- About 20% of long-term Co-60 supply is expected from Russian reactors, up to about 50% in a given year, exposed to sanctions and shipping licence renewals.
- EO regulation
- EPA NESHAP rules, the FIFRA Interim Decision and California requirements impose new emission controls and worker exposure limits; in the U.S. Sterigenics buys all its EO from one supplier.
- Softer med device demand
- Med device demand softened from mid-to-late Q3 2026, mostly among European customers, and continued into early Q4.
What leadership says
“my primary goal is to be able to accelerate growth within this business. We got to become more essential to our customers. We've got to become easier to work with.”
“We've got approximately 70% of our Sterigenics and Nelson Labs revenue comes from shared customers and we obviously need to focus on penetrating these accounts with our full offering.”
“this is an incredibly resilient business.”
“We definitely see a meaningful step down in CapEx next year”
Where a supplier can help
- Emission control and EHS solutions
- Tied to EO regulation and the facility enhancements finishing in Q1 2027: emission control, monitoring and worker-safety suppliers fit the about $51 million of 2026 environmental capex.
- Construction and equipment for new capacity
- Tied to sterilization capacity expansion: builders and equipment vendors can support the second greenfield project and X-ray capacity.
- Cross-selling and CRM tooling
- Tied to the One Sotera priority: account management and CRM tools help penetrate shared Sterigenics and Nelson Labs customers with the full offering.
- Supply chain risk management
- Tied to Co-60 supply concentration and the single EO supplier: sourcing, logistics and risk-monitoring partners address supply exposure.
- Lab capacity for pharma testing
- Tied to the Nelson Labs pharma testing expansion: lab equipment, LIMS and staffing partners support growth in core lab testing.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Sotera Health Company?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Sotera Health Company Annual Report on Form 10-K for fiscal year 2025
- Sotera Health is a global provider of end-to-end sterilization, lab testing and advisory services for the healthcare industry, with 62 facilities and over 3,000 employees; in 2025 its customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies.
- FY2025 net revenues were $1,163.6 million (+5.7%; about 5.2% at constant currency), net income $77.9 million, Adjusted Net Income $245.4 million and Adjusted EBITDA $593.8 million (+8.2%); all three segments grew segment income.
- Three reportable segments: Sterigenics (terminal sterilization, $755.8 million revenue, 54.6% segment margin), Nordion (Co-60 and gamma irradiation systems, $187.6 million, 57.3%) and Nelson Labs (lab testing and advisory, $220.2 million, 33.3%).
- Sterigenics plus Nordion make Sotera the only vertically integrated global gamma sterilization provider; more than 90% of Sterigenics' revenues and about 90% of Nordion's come from customers under multi-year contracts.
- Growth investments: two active capacity expansion projects at Sterigenics, a new X-ray facility in final qualification, Co-60 development with Westinghouse/PSEG and at Darlington (Ontario), and lab expansion for pharma testing at Nelson Labs. 2025 capex was $138.0 million; about $51 million of 2026 capex relates to environmental facility enhancements.
- Ethylene oxide (EO) litigation is the main overhang: Illinois settlements of $30.9 million (97 claims) and $34.0 million (129 claims) in 2025; about 450 personal injury claims pending in Georgia and about 120 claims in California, with initial trials scheduled for January and April 2027. EO litigation and professional fees were $46.2 million in 2025.
- Supply risk: about 20% of long-term Co-60 supply is expected from Russian reactors (up to about 50% in a given year); a single EO supplier serves the U.S. industry.
- Balance sheet: $1,419.5 million term loan and $750.0 million of 7.375% senior secured notes; cash of $346.5 million at year end; operating cash flow $287.2 million.
- Leadership at filing: Michael B. Petras, Jr. (Chairman and CEO since 2016), Jon Lyons (CFO), Mike Rutz (President of Sterigenics), Alex Dimitrief (General Counsel).
- Sotera Health Company Quarterly Report on Form 10-Q for Q3 2026
- Q3 2026 net revenues $324.9 million (+4.4%), net income $58.4 million, Adjusted Net Income $82.5 million and Adjusted EBITDA $170.7 million (+3.9%).
- Nine months 2026: revenues $926.3 million (+7.7%; about 6.3% excluding FX), net income $138.6 million (vs $43.1 million, which included $64,943 thousand of Illinois EO settlements), Adjusted EBITDA $471.1 million (+7.9%).
- Sterigenics Q3 revenue $209.3 million (+8.5%: pricing 4.8%, volume/mix 3.4%), segment margin 56.1%; it now uses four technologies including X-Ray.
- Nordion Q3 revenue $55.0 million (-12.4%) on Co-60 harvest timing, but margin rose to 61.3%; nine-month revenue +6.1%.
- Nelson Labs Q3 revenue $60.6 million (+8.8%: volume/mix 6.6%, pricing 2.6%), margin 32.1% on business mix.
- Capex accelerated to $145.5 million in nine months (vs $87.3 million); operating cash flow $228.5 million despite the $34.0 million Illinois settlement paid in February 2026.
- Term loan repriced again in May 2026 (Amendment No. 7) to SOFR + 2.25% on $1,415.9 million; weighted average rate 6.44% in Q3; cash $412.4 million.
- Sotera Health Q3 2026 earnings call transcript
- New CEO Alton Shader reported Q3 2026 constant currency revenue growth of 4.4% and adjusted EBITDA growth of 4%, with adjusted EBITDA margin up nearly 100 basis points sequentially to 52.5%.
- Sterigenics grew 8.2% at constant currency, but med device demand softened from mid-to-late Q3: "Primarily, that softness came from our European customers."; Q4 Sterigenics growth guided to about 6%, flat sequentially.
- Nelson Labs grew 9.2% on expert advisory services (EAS) projects, including urgent testing for a product used in a significant percentage of surgeries; full-year guide raised to low to mid-single digits.
- Nordion revenue fell 11.5% at constant currency on Co-60 harvest timing, yet margin rose 71 basis points to 61.3%.
- 2026 outlook reaffirmed: revenue $1.233-1.250 billion (5.25%-6.75% constant currency growth), adjusted EBITDA $632-641 million, adjusted EPS of 95 cents to a dollar and one cent, capex $200-225 million.
- Net leverage reached 2.9x (target 2-3x) and Moody's upgraded the rating; EO facility enhancements finish in Q1 2027 and capex should step down meaningfully in 2027.
- About 70% of Sterigenics and Nelson Labs revenue comes from shared customers, the base of the cross-business-unit selling push.
- Litigation: Georgia appellate decision due by spring 2027; first California trials in January and April 2027.
- Sotera Health Q2 2026 earnings call transcript
- First earnings call of CEO Alton Shader (in post since May 26, 2026, after 25 years in healthcare); Michael Petras became Executive Chairman after ten years as CEO.
- Q2 2026: revenue $321 million (+9.2%, 8% at constant currency), adjusted EBITDA $166 million (+10%), margin 51.6%, adjusted EPS $0.26 (+30%).
- Sterigenics +7% constant currency, Nordion +16.7% on Co-60 harvest timing, Nelson Labs +5.4% after winning time-sensitive customer work.
- 2026 outlook raised to 5.25%-6.75% constant currency revenue growth and 5.75%-7.25% adjusted EBITDA growth; capex $200-225 million.
- Former private equity sponsors sold their last shares in May; Riaz Bandali moved from Nordion President to lead Nelson Labs after Joseph Shrawder retired.
- Shader's priorities: understand the business and talent, deepen customer partnership, build a customer-first culture and push the "One Sotera" cross-business-unit offering; his goal is "to accelerate growth".
- North Carolina X-ray facility starts revenue in Q3; a second greenfield project is back on and due around end of 2027 or early 2028.
- Net leverage reached 3x, inside the 2-3x target; New Mexico EO suit settled in July for an immaterial amount.
Questions about Sotera Health Company
What does Sotera Health do?
Sotera Health sterilizes medical, pharmaceutical and food products through Sterigenics, supplies Co-60 through Nordion and runs lab testing and advisory services through Nelson Labs.
What is Sotera Health's revenue?
FY2025 net revenues were $1,163.6 million, up 5.7%. 2026 revenue is guided at $1.233-1.250 billion.
How many employees does Sotera Health have?
Sotera Health had over 3,000 employees across 62 facilities at December 31, 2025.
Who leads Sotera Health?
Alton Shader became CEO on May 26, 2026; Michael Petras is Executive Chairman after ten years as CEO, and Jon Lyons is CFO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)